BRPI0718183B8 - proteína hemaglutinina h5 de vírus influenza e seus usos, vacina, seu processo de produção e seus usos, bem como kit de partes - Google Patents

proteína hemaglutinina h5 de vírus influenza e seus usos, vacina, seu processo de produção e seus usos, bem como kit de partes

Info

Publication number
BRPI0718183B8
BRPI0718183B8 BRPI0718183A BRPI0718183A BRPI0718183B8 BR PI0718183 B8 BRPI0718183 B8 BR PI0718183B8 BR PI0718183 A BRPI0718183 A BR PI0718183A BR PI0718183 A BRPI0718183 A BR PI0718183A BR PI0718183 B8 BRPI0718183 B8 BR PI0718183B8
Authority
BR
Brazil
Prior art keywords
well
vaccine
kit
protein
parts
Prior art date
Application number
BRPI0718183A
Other languages
English (en)
Portuguese (pt)
Inventor
M Vaughn Eric
Juergen Daemmgen
Carlos Gonzales-Hernandez Paulino
Original Assignee
Boehringer Ingelheim Animal Health Usa Inc
Boehringer Ingelheim Vetmedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Animal Health Usa Inc, Boehringer Ingelheim Vetmedica Inc filed Critical Boehringer Ingelheim Animal Health Usa Inc
Publication of BRPI0718183A2 publication Critical patent/BRPI0718183A2/pt
Publication of BRPI0718183B1 publication Critical patent/BRPI0718183B1/pt
Publication of BRPI0718183B8 publication Critical patent/BRPI0718183B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0718183A 2006-10-27 2007-10-26 proteína hemaglutinina h5 de vírus influenza e seus usos, vacina, seu processo de produção e seus usos, bem como kit de partes BRPI0718183B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86314206P 2006-10-27 2006-10-27
US60/863,142 2006-10-27
US11/923,326 2007-10-24
US11/923,326 US8202967B2 (en) 2006-10-27 2007-10-24 H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
PCT/US2007/082699 WO2008052173A2 (en) 2006-10-27 2007-10-26 Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use

Publications (3)

Publication Number Publication Date
BRPI0718183A2 BRPI0718183A2 (pt) 2013-11-05
BRPI0718183B1 BRPI0718183B1 (pt) 2020-03-17
BRPI0718183B8 true BRPI0718183B8 (pt) 2022-05-24

Family

ID=39325469

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0718183A BRPI0718183B8 (pt) 2006-10-27 2007-10-26 proteína hemaglutinina h5 de vírus influenza e seus usos, vacina, seu processo de produção e seus usos, bem como kit de partes

Country Status (18)

Country Link
US (3) US8202967B2 (cg-RX-API-DMAC7.html)
EP (1) EP2086576B8 (cg-RX-API-DMAC7.html)
JP (2) JP5442442B2 (cg-RX-API-DMAC7.html)
KR (2) KR101520307B1 (cg-RX-API-DMAC7.html)
AU (1) AU2007308869B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0718183B8 (cg-RX-API-DMAC7.html)
CA (1) CA2664914C (cg-RX-API-DMAC7.html)
CO (1) CO6210831A2 (cg-RX-API-DMAC7.html)
DK (1) DK2086576T3 (cg-RX-API-DMAC7.html)
ES (1) ES2391123T3 (cg-RX-API-DMAC7.html)
MX (1) MX2009004243A (cg-RX-API-DMAC7.html)
MY (1) MY150226A (cg-RX-API-DMAC7.html)
PL (1) PL2086576T3 (cg-RX-API-DMAC7.html)
PT (1) PT2086576E (cg-RX-API-DMAC7.html)
RU (1) RU2479589C2 (cg-RX-API-DMAC7.html)
SG (1) SG176419A1 (cg-RX-API-DMAC7.html)
SI (1) SI2086576T1 (cg-RX-API-DMAC7.html)
WO (1) WO2008052173A2 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101300023A (zh) * 2005-10-28 2008-11-05 贝林格尔·英格海姆维特梅迪卡有限公司 用于治疗/预防流感病原体在物种间传播的疫苗的用途
US8202967B2 (en) * 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
WO2008113011A2 (en) 2007-03-14 2008-09-18 Ligocyte Pharmaceuticals, Inc. Virus like particle purification
MX2011005604A (es) 2008-11-28 2011-09-01 Merial Ltd Vacuna recombinante para influenza aviar y sus usos.
WO2011112871A1 (en) * 2010-03-11 2011-09-15 Immune Design Corp. Vaccines for pandemic influenza
SG10201709806VA (en) 2010-10-04 2017-12-28 Massachusetts Inst Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
AR088028A1 (es) * 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
MX360137B (es) * 2013-02-21 2018-10-24 Boehringer Ingelheim Vetmedica Gmbh Proteínas h5 del virus de la influenza h5n1 para usarse como un medicamento.
JP2015015931A (ja) * 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ ウイルス様粒子を含む培養物の製造方法
JOP20190088A1 (ar) 2016-10-21 2019-04-21 Us Agriculture نواقل مؤتلفة للتعبير عن مولدات مضاد فيروس انفلونزا الطيور و استخداماتها
MX2021005257A (es) * 2018-11-06 2021-06-18 Boehringer Ingelheim Vetmedica Gmbh Composicion inmunogenica contra el subtipo h5 del virus de la influenza aviar.
CN117229370B (zh) * 2022-06-08 2024-11-01 中科南京生命健康高等研究院 H5n6禽流感广谱性疫苗的开发及其应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US382425A (en) 1888-05-08 Brandt
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4769331A (en) 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4552758A (en) * 1983-12-20 1985-11-12 St. Jude Children's Research Hospital Human use of avian-human reassortants as vaccines for influenza A virus
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
IL84154A0 (en) 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
EP0386185A1 (fr) 1988-07-29 1990-09-12 IntraCel Corporation Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
DK0737750T3 (da) 1989-03-21 2003-09-01 Vical Inc Ekspression af exogene polynucleotidsekvenser i vertebrater
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5552143A (en) 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
US5690938A (en) 1989-07-07 1997-11-25 Oravax, Inc. Oral immunization with multiple particulate antigen delivery system
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
GB9001766D0 (en) 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
US5643577A (en) 1990-04-24 1997-07-01 The University Of Newcastle Research Associates Limited Oral vaccine comprising antigen surface-associated with red blood cells
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
JP3602530B2 (ja) 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
EP0561034B1 (en) 1991-08-26 1999-06-09 IMMUNO Aktiengesellschaft Direct molecular cloning of a modified chordopox virus genome
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5807722A (en) 1992-10-30 1998-09-15 Bioengineering Resources, Inc. Biological production of acetic acid from waste gases with Clostridium ljungdahlii
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
IL108915A0 (en) 1993-03-18 1994-06-24 Merck & Co Inc Polynucleotide vaccine against influenza virus
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
DE69536091D1 (de) 1994-01-27 2010-09-09 Univ Massachusetts Medical Immunisierung durch Impfung von DNS Transkriptionseinheit
DE69534289T2 (de) 1994-04-29 2006-04-27 Baxter Healthcare S.A. Rekombinante Pockenviren mit fremden Polynukleotiden in wichtigen Regionen
JPH11502222A (ja) 1995-03-23 1999-02-23 キャンタブ ファーマシューティカルズ リサーチ リミティド 遺伝子供給用ベクター
DE69740033D1 (de) 1996-07-03 2010-12-09 Merial Inc Rekombinanter hunde-adenovirus 2 (cav2), welcher exogene dna enthält
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
US6204281B1 (en) * 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
CN100489107C (zh) 2000-04-28 2009-05-20 圣朱德儿童研究医院 用于产生感染性流感病毒的dna转染系统
AU2002218742A1 (en) 2000-07-11 2002-01-21 Johns Hopkins University Application of photochemotherapy for the treatment of cardiac arrhythmias
JPWO2002062381A1 (ja) * 2001-02-05 2004-06-03 久光製薬株式会社 バキュロウイルスベクターワクチン
WO2003013609A1 (fr) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Medicaments a liberation continue
CA2491568A1 (en) 2002-08-27 2004-03-11 Dow Agrosciences Llc Use of escherichia coli heat labile toxin as an adjuvant in birds and poultry
CA2529647C (en) * 2003-06-16 2013-08-13 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
WO2005004222A1 (en) 2003-07-04 2005-01-13 Koninklijke Philips Electronics N.V. Precursor solution, method of preparation thereof and use thereof
EP1722815A1 (en) 2004-03-09 2006-11-22 Chiron Corporation Influenza virus vaccines
EP2530147B1 (en) 2004-05-25 2014-09-10 MedImmune, LLC Influenza hemagglutinin and neuraminidase variants
CN1748795A (zh) * 2004-09-17 2006-03-22 金宁一 多价禽流感重组活载体疫苗
RU2283139C1 (ru) * 2005-03-21 2006-09-10 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Способ получения антигенов для вакцины против вирусов гриппа
KR20080052509A (ko) * 2005-04-11 2008-06-11 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 애즈 레프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈, 센터스 포 디지즈 컨트롤 앤드 프리벤션 유행성 독감 바이러스에 대한 백신
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
CA2625406C (en) 2005-10-18 2016-08-09 Novavax, Inc. Functional influenza virus like particles (vlps)
CN101300023A (zh) * 2005-10-28 2008-11-05 贝林格尔·英格海姆维特梅迪卡有限公司 用于治疗/预防流感病原体在物种间传播的疫苗的用途
US20100150941A1 (en) 2006-09-13 2010-06-17 Dso National Laboratories Hemagglutinin antibody and uses thereof
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
WO2011136738A1 (en) 2010-04-30 2011-11-03 Temasek Life Sciences Laboratory Limited Universal vaccine against h5n1 lineages
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
MX360137B (es) 2013-02-21 2018-10-24 Boehringer Ingelheim Vetmedica Gmbh Proteínas h5 del virus de la influenza h5n1 para usarse como un medicamento.

Also Published As

Publication number Publication date
KR20090078362A (ko) 2009-07-17
BRPI0718183A2 (pt) 2013-11-05
WO2008052173A3 (en) 2008-11-13
US8592558B2 (en) 2013-11-26
JP2014012008A (ja) 2014-01-23
DK2086576T3 (da) 2012-10-15
US20120231027A1 (en) 2012-09-13
WO2008052173A9 (en) 2012-03-22
US8202967B2 (en) 2012-06-19
SG176419A1 (en) 2011-12-29
AU2007308869A1 (en) 2008-05-02
JP2010508030A (ja) 2010-03-18
MY150226A (en) 2013-12-31
CA2664914C (en) 2016-11-22
KR20150041200A (ko) 2015-04-15
WO2008052173A8 (en) 2011-02-03
PL2086576T3 (pl) 2012-12-31
WO2008052173A2 (en) 2008-05-02
US9375469B2 (en) 2016-06-28
EP2086576B8 (en) 2015-02-18
US20140050755A1 (en) 2014-02-20
CO6210831A2 (es) 2010-10-20
US20080193471A1 (en) 2008-08-14
MX2009004243A (es) 2009-05-14
RU2479589C2 (ru) 2013-04-20
KR101520307B1 (ko) 2015-05-29
RU2009119597A (ru) 2010-12-10
JP5442442B2 (ja) 2014-03-12
AU2007308869B2 (en) 2013-10-24
BRPI0718183B1 (pt) 2020-03-17
EP2086576B1 (en) 2012-07-18
EP2086576A2 (en) 2009-08-12
PT2086576E (pt) 2012-10-11
ES2391123T3 (es) 2012-11-21
SI2086576T1 (sl) 2012-11-30
EP2086576A4 (en) 2011-01-19
CA2664914A1 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
BRPI0718183B8 (pt) proteína hemaglutinina h5 de vírus influenza e seus usos, vacina, seu processo de produção e seus usos, bem como kit de partes
BR112019005587A2 (pt) proteínas de ligação recombinantes e sua utilização
BR112015005987A2 (pt) vacina, métodos para induzir uma resposta imune contra um antígeno hbv, para proteção de um sujeito da infeção por hbv, para proteger o sujeito que foi diagnosticado com uma infecção por hbv, para induzir uma resposta imune contra um antígeno do hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um sujeito contra infecção por hbv e para proteger o sujeito que foi diagnosticado com uma infecção por hbv, molécula de ácido nucleico, e, proteína
BR112012017695A2 (pt) polissiloxanas com grupos amônio quaternários, processo para sua preparação e seu uso em formulações de limpeza e para os cuidados
ECSP088262A (es) Proteínas de fusión de albúmina
EP2672992A4 (en) FOR A HEPATITIS B-VIRUS CORE PROTEIN, CODING NUCLEIC ACID MOLECULE AND VACCINE WITH IT
BRPI1015053A2 (pt) partículas similares a vírus da influenza quiméricas compreendendo hemaglutinina
BR112012029588A2 (pt) materiais biológicas relacionados a her3.
BR112015012152A2 (pt) Proteína de fusão terapêutica direcionada que compreende uma enzima lisossomal, ácido nucleico, composição farmacêutica, método para produzir a dita proteína e usos da proteína para tratar uma doença de armazenamento lisossomal e mucopolissacaridose tipo iiib
HRP20201815T1 (hr) Nukleinske kiseline za liječenje alergija
WO2012054907A3 (en) Novel hemagglutinin 5 (h5) proteins for the treatment and prevention of influenza infections
RU2013108067A (ru) Противогриппозная вакцина
CL2020001901A1 (es) Vacunas contra virus de la gripe y usos de las mismas.
BR112018017174A2 (pt) conjugados de aminoácido e peptídeo e processo de conjugação
EA200971059A1 (ru) Лечение и профилактика гриппа
BRPI1012078A2 (pt) construto de proteína, composição imunogênica, molécula de ácido nucleico , métodos de induzir uma resposta imune a casb7439 e de tratar um animal humano ou não-humano, e, uso de uma composição imunogênica
BR112013000992A2 (pt) métodos para intensificar traços relacionados ao rendimento em plantas, construtos, usos de um construto, plantas, parte de plantas, células de plantas transformadas, métodos para a produção de uma planta transgênica, plantas transgênicas, partes colhíveis e produtos derivados de uma planta, usos de um ácido nucleico, moléculas de ácido nucleico isolado, polipeptídeos isolados e uso de ácidos nucleicos de rna helicase dead-box
NZ712713A (en) Attenuated swine influenza vaccines and methods of making and use thereof
BR112015013625A2 (pt) adjuvante de vacinação, preparação e vacinas contendo o mesmo
AR063427A1 (es) Proteinas h5, moleculas de acido nucleico y vectores que las codifican y su uso medicinal
CR11384A (es) Proteina m de estreptococo, fragmentos inmunogenicos, acidos nucleicos y metodos de uso
AR060797A1 (es) Composicion farmaceutica que comprende la proteina nmb0606
BR112013013960A8 (pt) Composi%c3%87%c3%95es de vacinas de mal%c3%81ria, polipept%c3%8ddeos, fragmentos do mesmo, mol%c3%89culas de %c3%81cido nucleico, e usos destes
AR060796A1 (es) Composicion farmaceutica que comprende la proteina nmb0938
CU23584A1 (es) Composición farmacéutica que comprende la proteína nmb1796

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC. (US)

B25G Requested change of headquarter approved

Owner name: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC. (US)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/03/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/10/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B22E Other requirements [chapter 22.5 patent gazette]

Free format text: FORMULADA EXIGENCIA PARA ADEQUACAO OU CUMPRIMENTO DE DISPOSICOES LEGAIS NO PRAZO DE 60 (SESSENTA) DIAS DESTA DATA.

B16B Notification of grant cancelled [chapter 16.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 16.3 NA RPI NO 2629 DE 25/05/2021 POR TER SIDO INDEVIDA.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: RETIFICACAO REF. RPI 2567, DE 17/03/2020. PRAZO DE VALIDADE: 10 ANOS CONTADOS A PARTIR DE 17/03/2020, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME A ADI 5.529/DF, COM APOSTILAMENTO DO PRAZO DE VALIDADE DA PROTECAO DA MATERIA RELATIVA A PRODUTOS E PROCESSOS FARMACEUTICOS E EQUIPAMENTOS E/OU MATERIAIS DE USO EM SAUDE, PARA APLICACAO EM HUMANOS.